We may earn a commission when readers sign up through partner links. Rankings reflect our published methodology, not advertiser fees.
GLP·Agonists Editor's Pick

Condition · Evidence Review

GLP-1 and PCOS: Evidence, Fertility, Practical Use

Fact-checked by Dr. Adam Kennah, MD on . See our fact-checking policy.

Polycystic ovary syndrome (PCOS) affects roughly 10% of women of reproductive age. Insulin resistance sits at its mechanistic core, and weight loss reliably improves every PCOS feature — cycles, hyperandrogenism, fertility, and metabolic risk. Multiple small randomized trials have now tested GLP-1 receptor agonists specifically in PCOS, and results are consistently favorable. There is, however, no FDA indication.

Key facts

  • FDA status: No GLP-1 is approved for PCOS. Use is off-label.
  • Evidence base: Multiple small RCTs (liraglutide, semaglutide) showing improved weight, insulin sensitivity (HOMA-IR), menstrual regularity, and free androgen index.
  • Effect size: Weight loss in PCOS-specific trials is similar to non-PCOS obesity trials — roughly 8–12% with semaglutide at 1.0 mg, larger at 2.4 mg.
  • Fertility caveat: GLP-1s must be discontinued 2 months before attempting conception. Animal reproductive data is not reassuring.

Why PCOS responds to GLP-1 therapy

PCOS pathophysiology runs through insulin resistance: high circulating insulin drives ovarian androgen production, suppresses sex hormone-binding globulin (raising free androgen), disrupts the LH/FSH ratio, and impairs ovulation. Anything that improves insulin sensitivity (metformin, lifestyle weight loss, bariatric surgery) improves the downstream features. GLP-1 agonists do so via weight loss plus direct insulin-sensitizing effects.

What the trials show

The strongest individual trial is a 2022 head-to-head of semaglutide 1.0 mg vs metformin in 119 women with PCOS and BMI ≥30. Semaglutide produced significantly greater weight loss (~9% vs ~2%), greater reduction in HOMA-IR, greater reduction in free androgen index, and higher rates of menstrual regularity restoration at 32 weeks.

Liraglutide has a deeper evidence base in PCOS because it has been around longer. Meta-analyses consistently show improvement in weight, BMI, insulin sensitivity, and androgen profile.

Fertility and conception planning

This is the most consequential clinical caveat. GLP-1 agonists must be stopped before attempting pregnancy. The recommended washout is at least 2 months for semaglutide (its long half-life of ~7 days requires ~5 half-lives for full clearance). Animal studies show adverse reproductive effects; human pregnancy data is limited and not reassuring.

Paradoxically, the weight loss from GLP-1 therapy may itself restore ovulation in women who were anovulatory. This makes contraception planning essential during therapy in any sexually active patient who could become pregnant.

Practical PCOS workflow

  1. Baseline labs: A1c, fasting insulin, lipid panel, total and free testosterone, SHBG, LH, FSH.
  2. Confirm contraception plan if patient is reproductive-age and not actively trying to conceive.
  3. Initiate with standard titration. Combination with metformin is reasonable and synergistic.
  4. Reassess at 6 months: cycles, weight, free androgen index, A1c.
  5. If patient wishes to conceive: discontinue GLP-1, wait 2 months, then attempt conception.

What we still don't know

No phase 3 trial has tested semaglutide or tirzepatide specifically for a PCOS endpoint. There is no formal indication, no FDA label language, and no large head-to-head against current standard of care (metformin + lifestyle). The evidence is consistent and biologically plausible but smaller in scale than for obesity or T2D.

References

See our research bibliography for the semaglutide vs metformin PCOS trial and liraglutide PCOS meta-analyses.